Sign in
Taking peoplePhase 3

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

Key facts

Who runs it
Australian and New Zealand Intensive Care Research Centre
Where
Australia, Belgium, Finland, Germany, Ireland, New Zealand, Saudi Arabia, Slovenia, and Switzerland41 sites in 9 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
2,500 people, planned
Started
9 Nov 2020
Expected to end
31 Aug 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Epoetin Alfa 40000 UNT/ML
  • Sodium Chloride 0.9%
Record updated
16 July 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Are ≥ 18 to ≤ 75 years of age
  • Are < 24 hours since primary traumatic injury
  • Are invasively mechanically ventilated
  • Are expected to stay in the ICU ≥ 48 hours
  • Have a haemoglobin not exceeding the upper limit of the applicable normal (ULN) reference range in clinical use at the treating institution
  • Have informed consent from a legal surrogate according to local law

Who cannot take part

  • Recent history of DVT, PE or other thromboembolic event (within previous 12 months or receiving concomitant anticoagulant treatment for this indication)
  • Treatment with EPO in the last 30 days
  • First dose of study drug unable to be given within 24 hours of primary injury
  • A chronic hypercoagulable disorder, including known malignancy
  • End stage renal failure (receives chronic dialysis)
  • GCS = 3 and fixed dilated pupils
  • Pregnancy or lactation or 3 months postpartum
  • Expected to die imminently (< 24 hours)
  • Known sensitivity to mammalian cell derived products
  • Known contraindication to epoetin alfa
  • Severe pre-existing physical or mental disability or severe co-morbidity that may interfere with the assessment of outcome
  • The treating physician believes it is not in the best interest of the patient to be randomised to this trial

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in 9 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in critically ill trauma patients.

Read full original descriptionShow less

2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting to the ICU will be recruited into the study from participating study centres in Australia, New Zealand, Europe, and Saudi Arabia.

The 2 groups in the trial

  • Erythropoietin (EPO)Existing treatment, for comparison

    Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.

    Treatment: Epoetin Alfa 40000 UNT/ML

  • PlaceboPlacebo, for comparison

    Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.

    Treatment: Sodium Chloride 0.9%

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised, Double-blind, Placebo-controlled Trial of Erythropoietin Alfa Versus Placebo in Mechanically Ventilated Critically Ill Patients Following Traumatic Injury
Fit questions
Built from NCT04588311, who can take part
Record updated
16 July 2025